Publications

LES PUBLICATIONS :
(2012; J Med Econ.;15(1):145-54. Epub 2011 Nov 4.)A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Voir le détails
(2012 Mar 6; Br J Haematol. doi: 10.1111/j.1365-2141.2012.09076.x. [Epub ahead of print] No abstract available) Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
Voir le détails
(2012 Jan; Ann Hematol.;91(1):39-46. Epub 2011 May 7.) Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.
Voir le détails
(2012 Apr; Leuk Res.;36(4):397-400. Epub 2011 Dec 15.) Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine
Voir le détails
(2011 Sep 15; Cell Cycle.;10(18):3168-75. Epub 2011 Sep 15.) Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Voir le détails
(2011 Nov; Leuk Res.;35(11):1530-3. Epub 2011 Jul 30) Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
Voir le détails
(2011 Mar 1; Cancer.;117(5):992-1000. doi: 10.1002/cncr.25545. Epub 2010 Oct 13) Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Voir le détails
(2011 Jun 15; Cancer.;117(12):2697-702. doi: 10.1002/cncr.25774. Epub 2011 Jan 10) Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
Voir le détails
(2011 Jul; Leukemia.;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Voir le détails
(2011 Jul; Leuk Res.;35(7):863-7. Epub 2011 Mar 10.) Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Voir le détails
(2011 Jan 13; Blood.;117(2):403-11. Epub 2010 Oct 12.) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Voir le détails
(2011 Feb; Haematologica.;96(2):319-22. Epub 2010 Nov 25) Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
Voir le détails
(2011 Feb 10; J Clin Oncol.;29(5):516-23. Epub 2011 Jan 10. Review.) Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Voir le détails
(2010 Sep; Leuk Res.;34(9):1143-50. Epub 2010 May 6) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
Voir le détails
(2010 Nov; Leuk Res.;34(11):1430-6. Epub 2010 Jun 26) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
Voir le détails
(2010 Nov; Leuk Res.;34(11):1410-6. Epub 2010 Jul 6. Review.) Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion
Voir le détails
(2010 May; Oncotarget.;1(1):34-42.) Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Voir le détails
(2010 Jun; Haematologica;95(6):892-9. Epub 2009 Dec 16.) Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies
Voir le détails
(2010 Jul; Leuk Res. ;34(7):864-70. Epub 2010 Feb 2.) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients. A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Voir le détails
(2010 Jan 20; J Clin Oncol. ;28(3):437-44. Epub 2009 Dec 14.) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Voir le détails
(2010 Dec; Crit Rev Oncol Hematol.;76(3):218-27. Epub 2010 May 6) Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes.
Voir le détails
(2010 Aug; Eur J Haematol.;85(2):130-8. Epub 2010 Apr 12) Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine.
Voir le détails
(2010 Apr; Expert Opin Biol Ther.;10(4):605-14. Review.) Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
Voir le détails
(2010 Apr; Br J Haematol.;149(2):244-9. Epub 2010 Feb 5. Erratum in: Br J Haematol. 2010 Jun;149(6):919. ) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
Voir le détails
(2008 Sep;13, Apoptosis) Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
Voir le détails
(2008 May;22, Leukemia.)Meeting report: myelodysplastic syndromes at ASH 2007
Voir le détails
(2008 May, Br J Haematol. ) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia
Voir le détails
(2008 Jul;7, Cell Cycle.) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts
Voir le détails
(2008 Jul, Leuk Res.)Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Voir le détails
(2008 Jul 8, Biochem Pharmacol) Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison
Voir le détails
(2008 Jul 23, Blood ) Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera.
Voir le détails
(2008 Jul 18, Leuk Res.) Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
Voir le détails
(2008 Jul 10, Cancer) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system
Voir le détails
(2008 Jan 15, Blood) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Voir le détails
(2008 Feb, Br J Haematol) The role of lenalidomide in the management of myelodysplasia with del 5q
Voir le détails
(2007 Nov, Leukemia) Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes.
Voir le détails
(2006 May;20 ,Leukemia) Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Voir le détails
(2005 Jan 27, Blood) Rescue of early stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant negative form of FADD.
Voir le détails
(2004 Jul 15, Blood.) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes
Voir le détails
(2004 Hematol J.) A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Voir le détails
(2003 Feb, Leukemia) Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Voir le détails
(2000 Mar;18, J Clin Oncol.) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation.
Voir le détails
(1999, Adv Exp Med Biol.) Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP).
Voir le détails
(1999 Apr;13, Leukemia) A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
Voir le détails
(1998 Sep, Br J Haematol. ) Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
Voir le détails